Sangamo Biosciences (SGMO) Stock Hold Rating Reiterated at Wedbush; The Price Target Given is $9.0000; Fidelity National Information Services, Inc. (FIS) Had 21 Bullish Analysts

May 21, 2018 - By Richard Conner

Fidelity National Information Services, Inc. (NYSE:FIS) Logo

Among 24 analysts covering Fidelity National Information Services (NYSE:FIS), 21 have Buy rating, 0 Sell and 3 Hold. Therefore 88% are positive. Fidelity National Information Services had 70 analyst reports since August 7, 2015 according to SRatingsIntel. Cowen & Co maintained Fidelity National Information Services, Inc. (NYSE:FIS) on Wednesday, October 11 with “Buy” rating. The rating was maintained by Oppenheimer with “Overweight” on Wednesday, November 1. The company was maintained on Wednesday, October 11 by Jefferies. JP Morgan maintained the shares of FIS in report on Wednesday, November 1 with “Overweight” rating. The firm has “Buy” rating given on Tuesday, October 31 by SunTrust. The firm earned “Buy” rating on Wednesday, July 12 by Oppenheimer. As per Thursday, August 3, the company rating was maintained by Barclays Capital. On Tuesday, February 6 the stock rating was maintained by Guggenheim with “Buy”. The firm earned “Buy” rating on Friday, April 15 by Compass Point. Robert W. Baird maintained it with “Outperform” rating and $115 target in Wednesday, January 24 report. See Fidelity National Information Services, Inc. (NYSE:FIS) latest ratings:

09/05/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $113 New Target: $115 Maintain
08/05/2018 Broker: Oppenheimer Rating: Buy New Target: $118.0000 Maintain
07/05/2018 Broker: Robert W. Baird Rating: Buy New Target: $115.0000 Maintain
02/05/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $112 New Target: $114 Maintain
05/04/2018 Broker: Stephens Rating: Buy New Target: $114.0000 Maintain
23/03/2018 Broker: SunTrust Rating: Buy New Target: $114.0000 Maintain
07/02/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $104 New Target: $118 Maintain
06/02/2018 Broker: Guggenheim Rating: Buy New Target: $104.0 Maintain
06/02/2018 Broker: Cowen & Co Rating: Buy New Target: $109.0 Maintain
06/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $116.0 Maintain

The broker have set target price per share of $9.0000 on Sangamo Biosciences (NASDAQ:SGMO) shares. This is -42.05% from the last stock close. In an analyst report issued to clients on 21 May, Wedbush reconfirmed their Hold rating on shares of SGMO.

Since January 2, 2018, it had 0 insider buys, and 17 insider sales for $2.72 million activity. 15,000 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares with value of $345,861 were sold by Herberts Curt A. III. $92,436 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was sold by Conner Edward R. on Tuesday, February 6. On Tuesday, May 15 the insider Yi Kathy sold $76,920. Mento Steven J sold $237,159 worth of stock or 11,520 shares. $235,080 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was sold by Ramasastry Saira.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.58 billion. The company??s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on August, 8. They expect $-0.11 earnings per share, up 35.29% or $0.06 from last year’s $-0.17 per share. After $-0.23 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -52.17% EPS growth.

Investors sentiment decreased to 1.4 in Q4 2017. Its down 0.17, from 1.57 in 2017Q3. It turned negative, as 16 investors sold Sangamo Therapeutics, Inc. shares while 42 reduced holdings. 35 funds opened positions while 46 raised stakes. 53.22 million shares or 2.49% more from 51.93 million shares in 2017Q3 were reported. Tiaa Cref Mgmt Ltd Co stated it has 883,382 shares. Citadel reported 321,648 shares. Jpmorgan Chase reported 0% stake. Bogle Inv Ltd Partnership De accumulated 966,128 shares or 1.16% of the stock. Mckinley Lc Delaware reported 0.08% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Keybank National Association Oh holds 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 37,809 shares. Legal & General Public Ltd Company holds 0% or 21,358 shares. Ameritas Invest Prtn invested 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Ubs Asset Americas holds 37,122 shares or 0% of its portfolio. Vigilant Capital Limited Liability has 0.01% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Parallax Volatility Advisers Lp owns 12,810 shares or 0% of their US portfolio. Atlantic Trust Grp Inc Limited Com accumulated 1,000 shares. Grp Incorporated, New York-based fund reported 56,481 shares. Teacher Retirement Of Texas holds 27,021 shares. Susquehanna Gp Inc Llp holds 311,330 shares or 0% of its portfolio.

The stock decreased 2.66% or $0.425 during the last trading session, reaching $15.525. About 1.49M shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 352.38% since May 21, 2017 and is uptrending. It has outperformed by 340.83% the S&P500.

More important recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Prnewswire.com which released: “Biotech Market Value Set to Grow Due to Technological Advancements” on May 21, 2018, also Seekingalpha.com published article titled: “Sangamo: The Secondary Was Ill-Timed Or Not”, Seekingalpha.com published: “Sangamo Therapeutics’ (SGMO) CEO Sandy Macrae on Q1 2018 Results – Earnings Call Transcript” on May 08, 2018. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was released by: Fool.com and their article: “Sangamo Therapeutics Stock History” with publication date: May 17, 2018.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences has $33.0 highest and $4 lowest target. $23’s average target is 48.15% above currents $15.525 stock price. Sangamo Biosciences had 26 analyst reports since August 8, 2015 according to SRatingsIntel. Jefferies maintained the shares of SGMO in report on Friday, October 13 with “Buy” rating. On Thursday, June 22 the stock rating was reinitiated by Jefferies with “Buy”. Jefferies maintained the shares of SGMO in report on Tuesday, September 12 with “Buy” rating. On Friday, December 4 the stock rating was initiated by Wells Fargo with “Outperform”. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Buy” rating given on Thursday, February 22 by Jefferies. Jefferies maintained the stock with “Buy” rating in Wednesday, September 2 report. The rating was maintained by Piper Jaffray on Thursday, August 10 with “Hold”. As per Tuesday, September 8, the company rating was downgraded by Zacks. Jefferies reinitiated Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Friday, October 23 with “Buy” rating. The rating was downgraded by Wedbush to “Neutral” on Tuesday, November 1.

Since December 15, 2017, it had 0 insider buys, and 7 insider sales for $87.77 million activity. Woodall James W. sold $8.76M worth of Fidelity National Information Services, Inc. (NYSE:FIS) on Wednesday, March 14. 17,000 shares were sold by HUNT DAVID K, worth $1.61M. MARTIRE FRANK R sold $37.84M worth of stock or 380,000 shares. 3,600 shares valued at $341,545 were sold by JAMES STEPHAN A on Tuesday, December 19.

The stock increased 0.26% or $0.27 during the last trading session, reaching $104.39. About 357,614 shares traded. Fidelity National Information Services, Inc. (NYSE:FIS) has risen 17.75% since May 21, 2017 and is uptrending. It has outperformed by 6.20% the S&P500.

More notable recent Fidelity National Information Services, Inc. (NYSE:FIS) news were published by: Bizjournals.com which released: “FIS extends relations with Minor League Baseball, Jumbo Shrimp” on May 21, 2018, also Globenewswire.com with their article: “Recent Analysis Shows TechnipFMC plc, Oceaneering International, FIS, Vista Outdoor, Taylor Morrison Home, and …” published on May 10, 2018, Businesswire.com published: “US Consumers are Unprepared for Coming Wealth Transfer, New FIS Study Finds” on May 16, 2018. More interesting news about Fidelity National Information Services, Inc. (NYSE:FIS) were released by: Businesswire.com and their article: “FIS Announces Quarterly Dividend” published on April 24, 2018 as well as Businesswire.com‘s news article titled: “FIS Announces Pricing of Senior Notes Offering” with publication date: May 14, 2018.

Investors sentiment increased to 1.11 in Q4 2017. Its up 0.04, from 1.07 in 2017Q3. It is positive, as 33 investors sold Fidelity National Information Services, Inc. shares while 191 reduced holdings. 72 funds opened positions while 177 raised stakes. 281.01 million shares or 1.76% less from 286.04 million shares in 2017Q3 were reported. State Of New Jersey Common Pension Fund D has invested 0.06% of its portfolio in Fidelity National Information Services, Inc. (NYSE:FIS). Timessquare Mngmt Ltd Liability reported 0.55% stake. Buffington Mohr Mcneal owns 56,817 shares for 2.05% of their portfolio. Nuveen Asset Mgmt Ltd Liability Co reported 53,981 shares or 0.03% of all its holdings. Northern Trust Corporation has invested 0.09% in Fidelity National Information Services, Inc. (NYSE:FIS). 2,718 are held by Sii Invests Inc Wi. Rhumbline Advisers reported 632,254 shares. Private Trust Na owns 5,919 shares. New York-based Eagle Lc has invested 1.21% in Fidelity National Information Services, Inc. (NYSE:FIS). Meritage Gp Lp invested in 3.39M shares or 5.36% of the stock. Blackrock Inc reported 0.1% stake. Ameritas Inv Prtn invested in 7,400 shares. Kbc Group Nv reported 0.03% stake. West Oak Ltd has 14,600 shares for 0.84% of their portfolio. Price T Rowe Inc Md holds 0.41% or 26.94 million shares in its portfolio.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>